MeSH tree: C04.557.450.565.370
Gastrointestinal stromal tumors (GISTs) are the most common type of sarcoma, often driven by mutations in the KIT or PDGFRA genes. Tyrosine kinase inhibitors (TKIs) like imatinib have been the cornerstone of treatment, but ...
Aug 27, 2025
0
2
British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare gastrointestinal cancer GIST.
Jan 13, 2025
0
0
A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors.
Nov 5, 2024
0
40
About 1,200 Germans are diagnosed with gastrointestinal stromal tumors every year—a rare type of cancer in which the tumors develop in the walls of the digestive organs and quickly develop resistance to common precision ...
Oct 15, 2024
0
0
Before a drug can be used to treat a disease, it must go through a lengthy and expensive trial process to prove both safety and effectiveness. By repurposing already-approved drugs, researchers can cut out the time and expense ...
Jan 12, 2024
0
12
Ripretinib is a tyrosine kinase inhibitor that was approved by the United States FDA in 2020 for treatment of advanced gastrointestinal stromal tumor (GIST) in patients who received prior treatment with three or more tyrosine ...
Nov 6, 2023
0
0
Researchers from the University of Colorado Anschutz Medical Campus have identified a new feature indicative of the chance of recurrence of Gastrointestinal Stromal Tumors (GISTs).
Jan 10, 2023
0
2
Researchers led by Prof. Zhang Xin at the Hefei Institutes of Physical Science of the Chinese Academy of Sciences (CAS) combined the 9.4 T static magnetic field (SMF) with a commonly used anti-cancer drug imatinib mesylate ...
Oct 14, 2022
0
7
